Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon Walmsley

Showing results (151-160 of 199) with videos related to

Pageof 20
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2015
Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination ProgramsAltynay Shigayeva, Wallis Rudnick, Karen Green, et al.
Frontiers in Immunology|June 12, 2024
Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE studyJosep M Llibre, Judith A Aberg, Sharon Walmsley, et al.
Implementation Science : IS|January 17, 2016
Enhanced syphilis screening among HIV-positive men (ESSAHM): a study protocol for a clinic-randomized trial with stepped wedge designAnn N Burchell, Vanessa G Allen, Ramandip Grewal, et al.
CMAJ Open|December 9, 2014
The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort studyMarina B Klein, Jim Young, David Dunn, et al.
BMC Infectious Diseases|November 23, 2019
Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada?Urvi Rana, Matt Driedger, Paul Sereda, et al.
Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal Officiel De L'Association Pour La Microbiologie Medicale Et L'Infectiologie Canada|November 7, 2022
Clinical and demographic predictors of antiretroviral efficacy in HIV-HBV co-infected patientsUrvi Rana, Matt Driedger, Paul Sereda, et al.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trialJean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, et al.
Antiviral Therapy|March 16, 2019
Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEPJaime Younger, Janet Raboud, Leah Szadkowski, et al.
Digital Health|September 22, 2025
Exploring factors influencing the adoption and use of digital health technology for HIV management among older adults living with HIV: A qualitative studyKristina M Kokorelias, Erica Dove, Dean Valentine, et al.
The New England Journal of Medicine|March 15, 2003
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South AmericaJacob P Lalezari, Keith Henry, Mary O'Hearn, et al.
Pageof 20

Showing results (151-160 of 199) with videos related to

Sort By:
Pageof 20
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2015
Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination ProgramsAltynay Shigayeva, Wallis Rudnick, Karen Green, et al.
Frontiers in Immunology|June 12, 2024
Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE studyJosep M Llibre, Judith A Aberg, Sharon Walmsley, et al.
Implementation Science : IS|January 17, 2016
Enhanced syphilis screening among HIV-positive men (ESSAHM): a study protocol for a clinic-randomized trial with stepped wedge designAnn N Burchell, Vanessa G Allen, Ramandip Grewal, et al.
CMAJ Open|December 9, 2014
The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort studyMarina B Klein, Jim Young, David Dunn, et al.
BMC Infectious Diseases|November 23, 2019
Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada?Urvi Rana, Matt Driedger, Paul Sereda, et al.
Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal Officiel De L'Association Pour La Microbiologie Medicale Et L'Infectiologie Canada|November 7, 2022
Clinical and demographic predictors of antiretroviral efficacy in HIV-HBV co-infected patientsUrvi Rana, Matt Driedger, Paul Sereda, et al.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trialJean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, et al.
Antiviral Therapy|March 16, 2019
Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEPJaime Younger, Janet Raboud, Leah Szadkowski, et al.
Digital Health|September 22, 2025
Exploring factors influencing the adoption and use of digital health technology for HIV management among older adults living with HIV: A qualitative studyKristina M Kokorelias, Erica Dove, Dean Valentine, et al.
The New England Journal of Medicine|March 15, 2003
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South AmericaJacob P Lalezari, Keith Henry, Mary O'Hearn, et al.
Pageof 20